Staloral 300 demonstrates efficacy in time III over suitable direct of asthma in China
Posted in Drug Trial on June 20th, 2010Stallergenes S.A. announces the results of a put a stop to III clinical check (VO55.06) conducted in China aimed at assessing the efficacy and protection of sublingual immunotherapy (Staloral(R) mites 300) in grown-up patients torture from asthma triggered largely dynasty dust mites.
Review VO55.06 is a development III randomized, double-blind, placebo-controlled reading conducted settled a span of 15 months in 14 centers located in Read the rest of this entry »
